Recombinant Human Clara Cell Secretory Protein Treatment Increases Lung mRNA Expression of Surfactant Proteins and Vascular Endothelial Growth Factor in a Premature Lamb Model of Respiratory Distress Syndrome

ABSTRACT

Infant respiratory distress syndrome (IRDS) can lead to impaired alveolarization and dysmorphic vascularization of bronchopulmonary dysplasia. Clara cell secretory protein (CC10) has anti-inflammatory properties but is deficient in the premature infant. Because surfactant and vascular endothelial growth factor (VEGF) profiles are impaired by inflammation and CC10 inhibits lung inflammation, we hypothesized that CC10 may up-regulate surfactant protein (SP) and VEGF expression. Preterm lambs (n = 24; 126 ± 3 days [standard error] gestation) with IRDS were randomized to receive 100 mg/kg surfactant, 100 mg/kg surfactant followed by intratracheal 0.5, 1.5, or 5 mg/kg rhCC10 and studied for 4 hours. Gas exchange and lung mechanics were monitored; surfactant protein and VEGF mRNA profiles in lung were assessed. There was a significant rhCC10 dose-dependent increase in respiratory compliance and ventilation efficiency index; both parameters were significantly greater in animals treated with 5 mg/kg rhCC10 than those treated with surfactant alone. Similarly, there was a significant rhCC10 dose and protein-dependent increase in surfactant protein (SP-B > SP-C > SP-A) and dose- and isoform-dependent increase in VEGF (VEGF189 > VEGF165 > VEGF121). These data demonstrate that early intervention with rhCC10 up-regulates surfactant protein and VEGF expression, supporting the role of CC10 to protect against hyperoxia and mechanical ventilation in the immature lung.

Clara cell secretory protein (CC10) - respiratory distress syndrome - mechanical ventilation - hyperoxia - surfactant protein expression - VEGF isoform expression - lung inflammation

REFERENCES

• 1 Jobe A H, Bancalari E. Bronchopulmonary dysplasia.  Am J Respir Crit Care Med. 2001;  163 1723-1729
• 2 Sano H, Kuroki Y. The lung collectins, SP-A and SP-D, modulate pulmonary innate immunity.  Mol Immunol. 2005;  42 279-287
• 3 LeVine A M, Whitsett J A. Pulmonary collectins and innate host defense of the lung.  Microbes Infect. 2001;  3 161-166
• 4 American Academy of Pediatrics—Committee on Fetus and Newborn, Canadian Paediatric Society—Fetus and Newborn Committee. Postnatal corticosteroids to treat or prevent chronic lung disease in preterm infants.  Pediatrics. 2002;  109 330-338
• 5 Stark A R, Carlo W A, Tyson J E et al.. Adverse effects of early dexamethasone in extremely-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.  N Engl J Med. 2001;  344 95-101
• 6 Watterberg K L, Carmichael D F, Gerdes J S, Werner S, Backstrom C, Murphy S. Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia.  J Pediatr. 1994;  125 264-269
• 7 Chen L C, Zhang Z, Myers A C, Huang S K. Cutting edge: altered pulmonary eosinophilic inflammation in mice deficient for Clara cell secretory 10-kDa protein.  J Immunol. 2001;  167 3025-3028
• 8 Peri A, Dubin N H, Dhanireddy R, Mukherjee A B. Uteroglobin gene expression in the rabbit uterus throughout gestation and in the fetal lung. Relationship between uteroglobin and eicosanoid levels in the developing fetal lung.  J Clin Invest. 1995;  96 343-353
• 9 Oshika E, Liu S, Ung L P et al.. Glucocorticoid-induced effects on pattern formation and epithelial cell differentiation in early embryonic rat lungs.  Pediatr Res. 1998;  43 305-314
• 10 Ramsay P L, Demayo F J, Hegemier S E, Wearden M E, Smith C V, Welty S E. Clara cell secretory protein oxidation and expression in premature infants who develop bronchopulmonary dysplasia.  Am J Respir Crit Care Med. 2001;  164 155-161
• 11 Levin S W, Butler J D, Schumacher U K, Wightman P D, Mukherjee A B. Uteroglobin inhibits phospholipase A2 activity.  Life Sci. 1986;  38 1813-1819
• 12 Mantile G, Miele L, Cordella-Miele E, Singh G, Katyal S L, Mukherjee A B. Human Clara cell 10-kDa protein is the counterpart of rabbit uteroglobin.  J Biol Chem. 1993;  268 20343-20351
• 13 Chandra S, Davis J M, Drexler S et al.. Safety and efficacy of intratracheal recombinant human Clara cell protein in a newborn piglet model of acute lung injury.  Pediatr Res. 2003;  54 509-515
• 14 Miller T L, Shashikant B N, Melby J M, Pilon A L, Shaffer T H, Wolfson M R. Recombinant human Clara cell secretory protein in acute lung injury of the rabbit: effect of route of administration.  Pediatr Crit Care Med. 2005;  6 698-706
• 15 Miller T L, Shashikant B N, Pilon A L, Pierce R A, Shaffer T H, Wolfson M R. Effects of an intratracheally delivered anti-inflammatory protein (rhCC10) on physiological and lung structural indices in a juvenile model of acute lung injury.  Biol Neonate. 2005;  89 159-170
• 16 Levine C R, Gewolb I H, Allen K et al.. The safety, pharmacokinetics, and anti-inflammatory effects of intratracheal recombinant human Clara cell protein in premature infants with respiratory distress syndrome.  Pediatr Res. 2005;  58 15-21
• 17 Angert R M, Pilon A L, Chester D, Davis J M. CC10 reduces inflammation in meconium aspiration syndrome in newborn piglets.  Pediatr Res. 2007;  62 684-688
• 18 Shashikant B N, Miller T L, Welch R W, Pilon A L, Shaffer T H, Wolfson M R. Dose response to rhCC10-augmented surfactant therapy in a lamb model of infant respiratory distress syndrome: physiological, inflammatory, and kinetic profiles.  J Appl Physiol. 2005;  99 2204-2211
• 19 Miller T L, Shashikant B N, Pilon A L, Pierce R A, Shaffer T H, Wolfson M R. Effects of recombinant Clara cell secretory protein (rhCC10) on inflammatory-related matrix metalloproteinase activity in a preterm lamb model of neonatal respiratory distress.  Pediatr Crit Care Med. 2007;  8 40-46
• 20 Maniscalco W M, Watkins R H, D'Angio C T, Ryan R M. Hyperoxic injury decreases alveolar epithelial cell expression of vascular endothelial growth factor (VEGF) in neonatal rabbit lung.  Am J Respir Cell Mol Biol. 1997;  16 557-567
• 21 Maniscalco W M, Watkins R H, Pryhuber G S, Bhatt A, Shea C, Huyck H. Angiogenic factors and alveolar vasculature: development and alterations by injury in very premature baboons.  Am J Physiol Lung Cell Mol Physiol. 2002;  282 L811-823
• 22 Tambunting F, Beharry K D, Waltzman J, Modanlou H D. Impaired lung vascular endothelial growth factor in extremely premature baboons developing bronchopulmonary dysplasia/chronic lung disease.  J Investig Med. 2005;  53 253-262
• 23 Klekamp J G, Jarzecka K, Perkett E A. Exposure to hyperoxia decreases the expression of vascular endothelial growth factor and its receptors in adult rat lungs.  Am J Pathol. 1999;  154 823-831
• 24 Maniscalco W M, Watkins R H, Finkelstein J N, Campbell M H. Vascular endothelial growth factor mRNA increases in alveolar epithelial cells during recovery from oxygen injury.  Am J Respir Cell Mol Biol. 1995;  13 377-386
• 25 Compernolle V, Brusselmans K, Acker T et al.. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice.  Nat Med. 2002;  8 702-710
• 26 Kunig A M, Balasubramaniam V, Markham N E et al.. Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats.  Am J Physiol Lung Cell Mol Physiol. 2005;  289 L529-L535
• 27 Brown K R, England K M, Goss K L, Snyder J M, Acarregui M J. VEGF induces airway epithelial cell proliferation in human fetal lung in vitro.  Am J Physiol Lung Cell Mol Physiol. 2001;  281 L1001-L1010
• 28 Raoul W, Chailley-Heu B, Barlier-Mur A M, Delacourt C, Maitre B, Bourbon J R. Effects of vascular endothelial growth factor on isolated fetal alveolar type II cells.  Am J Physiol Lung Cell Mol Physiol. 2004;  286 L1293-L1301
• 29 Bhatt A J, Amin S B, Chess P R, Watkins R H, Maniscalco W M. Expression of vascular endothelial growth factor and Flk-1 in developing and glucocorticoid-treated mouse lung.  Pediatr Res. 2000;  47 606-613
• 30 Hosford G E, Olson D M. Effects of hyperoxia on VEGF, its receptors, and HIF-2alpha in the newborn rat lung.  Am J Physiol Lung Cell Mol Physiol. 2003;  285 L161-L168
• 31 Bhutani V K, Sivieri E M, Abbasi S, Shaffer T H. Evaluation of neonatal pulmonary mechanics and energetics: a two-factor least mean square analysis.  Pediatr Pulmonol. 1988;  4 150-158
• 32 Antunes M J, Cullen J A, Holt W J, Gauthier T W, Baumgart S, Greenspan J S. Continued pulmonary recovery observed after discontinuing extracorporeal membrane oxygenation.  Pediatr Pulmonol. 1994;  17 143-148
• 33 Khan A M, Shabarek F M, Kutchback J W, Lally K P. Effects of dexamethasone on meconium aspiration syndrome in newborn piglets.  Pediatr Res. 1999;  46 179-183
• 34 Notter R H, Egan E A, Kwong M S. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age.  Pediatr Res. 1985;  19 569-577
• 35 Bradford M M. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding.  Anal Biochem. 1976;  72 248-254
• 36 Mandal A K, Zhang Z, Ray R et al.. Uteroglobin represses allergen-induced inflammatory response by blocking PGD2 receptor-mediated functions.  J Exp Med. 2004;  199 1317-1330
• 37 Mandal A K, Ray R, Zhang Z, Chowdhury B, Pattabiraman N, Mukherjee A B. Uteroglobin inhibits prostaglandin F2alpha receptor-mediated expression of genes critical for the production of pro-inflammatory lipid mediators.  J Biol Chem. 2005;  280 32897-32904
• 38 Zhang Z, Kim S J, Chowdhury B et al.. Interaction of uteroglobin with lipocalin-1 receptor suppresses cancer cell motility and invasion.  Gene. 2006;  369 66-71
• 39 Khoor A, Gray M E, Singh G, Stahlman M T. Ontogeny of Clara cell-specific protein and its mRNA: their association with neuroepithelial bodies in human fetal lung and in bronchopulmonary dysplasia.  J Histochem Cytochem. 1996;  44 1429-1438
• 40 Bernard A, Thielemans N, Lauwerys R, Langhendries J P, Van Lierde M, Freund M M. Clara cell protein in human amniotic fluid: a potential marker of fetal lung growth.  Pediatr Res. 1994;  36 771-775
• 41 Monacci W T, Merrill M J, Oldfield E H. Expression of vascular permeability factor/vascular endothelial growth factor in normal rat tissues.  Am J Physiol. 1993;  264 C995-C1002
• 42 Cong Y, Hong D. Alveolus formation: what have we learned from genetic studies?.  J Appl Physiol. 2004;  97 1543-1548
• 43 Kuan S F, Rust K, Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides: surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage.  J Clin Invest. 1992;  90 97-106
• 44 Phelps D S, Floros J. Localization of pulmonary surfactant proteins using immunohistochemistry and tissue in situ hybridization.  Exp Lung Res. 1991;  17 985-995
• 45 Stripp B R, Reynolds S D, Boe I M et al.. Clara cell secretory protein deficiency alters Clara cell secretory apparatus and the protein composition of airway lining fluid.  Am J Respir Cell Mol Biol. 2002;  27 170-178
• 46 Watkins R H, D'Angio C T, Ryan R M, Patel A, Maniscalco W M. Differential expression of VEGF mRNA splice variants in newborn and adult hyperoxic lung injury.  Am J Physiol. 1999;  276 L858-L867
• 47 Wu Y Z, Medjane S, Chabot S et al.. Surfactant protein-A and phosphatidylglycerol suppress type IIA phospholipase A2 synthesis via nuclear factor-kappaB.  Am J Respir Crit Care Med. 2003;  168 692-699
• 48 Arbibe L, Koumanov K, Vial D et al.. Generation of lyso-phospholipids from surfactant in acute lung injury is mediated by type-II phospholipase A2 and inhibited by a direct surfactant protein A-phospholipase A2 protein interaction.  J Clin Invest. 1998;  102 1152-1160
• 49 Hite R D, Seeds M C, Safta A M et al.. Lysophospholipid generation and phosphatidylglycerol depletion in phospholipase A(2)-mediated surfactant dysfunction.  Am J Physiol Lung Cell Mol Physiol. 2005;  288 L618-L624